Marinus Pharmaceuticals(US:MRNS) Prnewswireยท2024-07-01 09:45Core Viewpoint - A class action securities lawsuit has been filed against Marinus Pharmaceuticals, Inc. for alleged securities fraud affecting investors between March 17, 2021, and May 7, 2024 [4]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for Marinus investors who were adversely affected by alleged securities fraud during the specified time frame [1]. - Investors have until August 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [2]. - The complaint alleges that defendants made false statements and concealed risks related to the Randomized Therapy in Status Epilepticus Trial (RAISE), including the potential failure to meet early-stopping criteria and the implications for the Phase 3 RAISE II trial [5]. Group 2: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [3]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [6].